Friedman succeeding Hoos at Scorpion
Plus: 4DMT hires Noriyuki Kasahara as CSO, and updates from SV, Omega, AbbVie Ventures, Nikang, Immunome, Wugen, Zevra and Quris
Axel Hoos has stepped down as CEO of oncology company Scorpion Therapeutics Inc. Hoos is succeeded by Adam Friedman, who joined as a part of founding team, served as CEO for seven months until August 2021; until most recently, he was president of corporate strategy and business development. The company also named Jeff Albers as executive chair and a board member, hired Mark Chao as CMO, and promoted Erica Jackson from EVP, biology to chief discovery officer. Albers was CEO of Blueprint Medicines Corp. (NASDAQ:BPMC) and became a strategic adviser to Scorpion last October; Chao was CEO of TenSixteen Bio Inc., a company he co-founded.
4D Molecular Therapeutics Inc. (NASDAQ:FDMT) hired Noriyuki Kasahara as CSO. Kasahara, a board member at 4DMT, is a professor of neurological surgery and radiation oncology at the University of California San Francisco Medical School...